C1ORF52 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 4.67589966746118E-10 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
2.7964000000047E-06 |
Normal-vs-Stage2 |
1.515130E-03 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
1.150130E-02 |
Stage1-vs-Stage2 |
6.863400E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
6.240500E-02 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
9.827700E-02 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
8.72789995831624E-09 |
Normal-vs-AfricanAmerican |
3.132000E-01 |
Normal-vs-Asian |
4.017600E-02 |
Caucasian-vs-AfricanAmerican |
5.998100E-02 |
Caucasian-vs-Asian |
6.527000E-01 |
AfricanAmerican-vs-Asian |
3.886000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
6.22409999999629E-05 |
Normal-vs-Female |
3.25170000003983E-06 |
Male-vs-Female |
9.547000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
4.621000E-03 |
Normal-vs-Extreme_Weight |
4.36080000000283E-05 |
Normal-vs-Obese |
5.441400E-03 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
1.328160E-01 |
Normal_Weight-vs-Obese |
2.036000E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
8.795600E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
4.748600E-01 |
Normal-vs-Age(41-60Yrs) |
2.396400E-03 |
Normal-vs-Age(61-80Yrs) |
1.82590000008531E-07 |
Normal-vs-Age(81-100Yrs) |
4.549600E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.975200E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.608000E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.652200E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.676400E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.703600E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.373800E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
2.784400E-01 |
Normal-vs-Grade 3 |
1.909220E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
8.931200E-01 |
Grade 2-vs-Grade 4 |
2.784400E-01 |
Grade 3-vs-Grade 4 |
1.909220E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
2.27509999728426E-08 |
Normal-vs-N1 |
2.520200E-02 |
N0-vs-N1 |
2.432000E-01 |
|
|